Enosi Life Sciences President and CSO Dr. Michael Shepard Speaks at 4th World Laureates Forum

The former 2019 Lasker-DeBakey Clinical Medical Research Award laureate spoke on the value of openness in finding solutions to science’s biggest questions

EUGENE, Ore., Nov. 30, 2021 /PRNewswire/ — Dr. Michael Shepard, President and Chief Scientific Officer of Enosi Life Sciences, a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, spoke as a guest of the World Laureates Association at its 4th World Laureates Forum in Shanghai, China earlier this month.

Dr. Shepard, an innovator in the field of biotechnology and pioneer in cancer research, won the 2019 Lasker-DeBakey Clinical Medical Research Award with colleagues Dr. Dennis J. Slamon and Axel Ullrich due to their work inventing Herceptin—a targeted antibody therapy for breast cancer. The treatment has saved over 500,000 women from aggressive breast cancer as a result of Dr. Shepard’s discovery and his collaborative approach to research.

“There’s no shortage of breakthroughs we can accomplish with open science,” said Dr. Shepard. “We must take a look at what prevents this type of collaboration and address these causes so that we can realize our full potential.”

The World Laureates Association, a non-political, non-religious, non-governmental organization is one of the world’s highest-profile organizations for laureates, having achieved the Nobel Prize, Wolf Prize, Lasker Award, Turing Award, MacArthur Fellowship, and Fields Medal. Both Dr. Shepard and the WLA are staunch advocates for international cooperation and the sharing of knowledge across borders.   

Increasing knowledge and growing value thanks to cooperation with peers has been a recurring theme throughout Dr. Shepard’s career, and that philosophy of a united approach has guided him in his latest work with Enosi Life Sciences. His partnership with co-founder, Sir Marc Feldman who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases, combined with his own research in humanized antibodies has led to Enosi’s development of breakthrough biologics.

Beyond Dr. Shepard’s research, Enosi has embraced his collaborative approach as is reflected by Enosi’s executive team, including recently named CEO Dr. Patrick William Gray. Together, Enosi will continue its work to develop the next-generation of autoimmune, cancer and acute inflammation therapies that induce disease regression and prevent relapse, while dramatically-reducing patient side effects.

About Enosi Life Sciences
Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases (Lasker Award, 2003); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins (Lasker award, 2019). Enosi Life Sciences combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Life Sciences, visit www.enosi-life.com.


Tom Becker – Investor Relations
Enosi-Life Sciences Corp.

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.